glp-1 maintenance Weight after discontinuation of therapies Added Value to GLP-1 Receptor

Future challenges: Advancements have been made, but some key issues still remain

Besides obesity, dysregulation of TNF production has been implicated in a variety of human diseases, including Alzheimers disease (91), cancer (92), rheumatoid arthritis (74), and IBD (93)

These discrepancies may stem from short observation periods and small sample sizes respectively (101, 102)

More than 250 clinicians signed a letter (PDF) to the Senate HELP Committee expressing concern about the lack of patient access to novel non-insulin diabetes and weight loss medications due to exorbitant prices set by manufacturers

50 Gastrointestinal Motility Disorders: Gastric and Intestinal Manifestations GLP-1 RAs reduce GI motility and prolong intestinal transit time, effects that have raised concerns regarding an increased risk of gastroparesis, intestinal obstruction, or ileus

UK regulatory guidance (MHRA, NICE, BNF) advises against GLP-1 use whilst breastfeeding owing to lack of robust human safety studies